Cagrilintide 5mg + Semaglutide 5mg Next Gen Weight Management Peptide Buy Online Okdermo Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination CagriSema 2026: Everything You Need to Know About the Next Gen Weight Loss Combination CagriSema Dual Pathway Metabolic Signaling Compound CagriSema combines two investigational molecules Cagrilintide (amylin analogue) and Semaglutide (GLP 1 receptor agonist), designed to influence key metabolic and appetite regulating pathways. Current Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial UCL Discovery New Weight Loss Drug CagriSema Shows Impressive Results in Clinical Trials